Comparison of immunohistochemistry and mRNA in situ hybridization in detecting thyroid transcription factor-1 expression in non-small cell lung carcinomas tissue

Jiang,Huiyong; Bai,Xiaoyan; Meng,Fanjun; Zhang,Xuefeng

doi:10.3892/ol.2015.3757

Comparison of immunohistochemistry and mRNA in situ hybridization in detecting thyroid transcription factor-1 expression in non-small cell lung carcinomas tissue

Authors:
- Huiyong Jiang
- Xiaoyan Bai
- Fanjun Meng
- Xuefeng Zhang
View Affiliations

Affiliations: Department of General Surgery, General Hospital of Shenyang Military Area Command, Shenyang, Liaoning 110840, P.R. China, Division of Nephrology, Nanfang Hospital, Southern Medical University and Guangdong Provincial Institute of Nephrology, Guangzhou, Guangdong 510515, P.R. China, Department of Gastroenterology, 202nd Hospital of the People's Liberation Army, Shenyang, Liaoning 110003, P.R. China
Published online on: September 29, 2015 https://doi.org/10.3892/ol.2015.3757
Pages: 3581-3584

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thyroid transcription factor-1 (TTF-1) reportedly possesses oncogenic and suppressive roles within the same tumor type and may play a dual function in the progression of lung cancer. Immunohistochemistry (IHC) and mRNA in situ hybridization (ISH) are commonly used methods for detecting protein or mRNA expression. The present study compared the concordance rate of the two methods in the evaluation of thyroid transcription factor‑1 (TTF‑1) expression in non‑small cell lung carcinoma (NSCLC) using tissue microarray‑based IHC and mRNA ISH. TTF‑1 protein and mRNA expression levels were examined in 196 cases of NSCLC. The IHC and mRNA ISH agreement was 91.3% (179/196), and near‑perfect agreement was observed between the two methods (κ‑coefficient, 0.848). There was no significant difference between IHC and mRNA ISH, as analyzed by the McNemar‑Bowker test (P=0.219). The present findings proved that IHC is comparable to mRNA ISH for evaluating TTF‑1 expression in NSCLC. These two methods can be used to detect TTF-1 expression in future studies.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, Hubbard DD, DuPage MJ, Whittaker CA, Hoersch S, et al: Suppression of lung adenocarcinoma progression by Nkx2-1. Nature. 473:101–104. 2011. View Article : Google Scholar : PubMed/NCBI
3	Mishra M, Morgan V, Hamati AK and Al-Abbadi M: Carcinoma of unknown primary: Check the liver… thanks to TTF-1. Tenn Med. 105:35–36. 2012.PubMed/NCBI
4	Ye J, Findeis-Hosey JJ, Yang Q, McMahon LA, Yao JL, Li F and Xu H: Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung. Appl Immunohistochem Mol Morphol. 19:313–317. 2011. View Article : Google Scholar : PubMed/NCBI
5	Nakamura N, Miyagi E, Murata S, Kawaoi A and Katoh R: Expression of thyroid transcription factor-1 in normal and neoplastic lung tissues. Mod Pathol. 15:1058–1067. 2002. View Article : Google Scholar : PubMed/NCBI
6	Tang X, Kadara H, Behrens C, Liu DD, Xiao Y, Rice D, Gazdar AF, Fujimoto J, Moran C, Varella-Garcia M, et al: Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: Implications in lung cancer pathogenesis and prognosis. Clin Cancer Res. 17:2434–2443. 2011. View Article : Google Scholar : PubMed/NCBI
7	Tanaka H, Yanagisawa K, Shinjo K, Taguchi A, Maeno K, Tomida S, Shimada Y, Osada H, Kosaka T, Matsubara H, et al: Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res. 67:6007–6011. 2007. View Article : Google Scholar : PubMed/NCBI
8	Bai XY and Shen H: Quantitative analysis of thyroid transcription factor-1 mRNA expressions in primary lung cancer and its metastatic foci. Nan Fang Yi Ke Da Xue Xue Bao. 28:20–25. 2008.(In Chinese). PubMed/NCBI
9	Feng RE: IASLC/ATS/ERS international multidisciplinary new classification of lung adenocarcinoma and its clinical significance. Zhonghua Jie He He Hu Xi Za Zhi. 35:95–96. 2012.(In Chinese). PubMed/NCBI
10	Li X, Wan L, Shen H, Geng J, Nie J, Wang G, Jia N, Dai M and Bai X: Thyroid transcription factor-1 amplification and expressions in lung adenocarcinoma tissues and pleural effusions predict patient survival and prognosis. J Thorac Oncol. 7:76–84. 2012. View Article : Google Scholar : PubMed/NCBI
11	Li X, Wan L, Geng J, Wu CL and Bai X: Aldehyde dehydrogenase 1A1 possesses stem-like properties and predicts lung cancer patient outcome. J Thorac Oncol. 7:1235–1245. 2012. View Article : Google Scholar : PubMed/NCBI
12	Jiang H, Bai X, Zhang C and Zhang X: Evaluation of Her2 gene amplification in breast cancer using nuclei microarray in situ hybridization. Int J Mol Sci. 13:5519–5527. 2012. View Article : Google Scholar : PubMed/NCBI
13	Ma H, Zhang X, Zhang X, Yang D, Meng L, Zhang Y and Zhou S: The effect of esculentoside A on lupus nephritis-prone BXSB mice. Arch Med Sci. 9:354–360. 2013. View Article : Google Scholar : PubMed/NCBI
14	Landis JR and Koch GG: A one-way components of variance model for categorical data. Biometric. 33:671–679. 1977. View Article : Google Scholar
15	Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G and Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 4:844–847. 1998. View Article : Google Scholar : PubMed/NCBI
16	Rimm DL, Camp RL, Charette LA, Olsen DA and Provost E: Amplification of tissue by construction of tissue microarrays. Exp Mol Pathol. 70:255–264. 2001. View Article : Google Scholar : PubMed/NCBI
17	von Wasielewski R, Mengel M, Wiese B, Rüdiger T, Müller-Hermelink HK and Kreipe H: Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial. Am J Clin Pathol. 118:675–682. 2002. View Article : Google Scholar : PubMed/NCBI
18	Braunschweig T, Chung JY and Hewitt SM: Tissue microarrays: Bridging the gap between research and the clinic. Expert Rev Proteomics. 2:325–336. 2005. View Article : Google Scholar : PubMed/NCBI
19	Fennell DA, Myrand SP, Nguyen TS, Ferry D, Kerr KM, Maxwell P, Moore SD, Visseren-Grul C, Das M and Nicolson MC: Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study. PLoS One. 9:e1074552014. View Article : Google Scholar : PubMed/NCBI
20	Kapila K, Al-Ayadhy B, Francis IM, George SS and Al-Jassar A: Subclassification of pulmonary non-small cell lung carcinoma in fine needle aspirates using a limited immunohistochemistry panel. J Cytol. 30:223–225. 2013. View Article : Google Scholar : PubMed/NCBI
21	Kalhor N, Zander DS and Liu J: TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material. Mod Pathol. 19:1117–1123. 2006.PubMed/NCBI